EPO (human):Fc (human) (rec.) (non-lytic)
| Code | Size | Price |
|---|
| CHI-HF-220EPO-C050 | 50 ug | £385.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Target Species: Human
Shipping:
BI
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Erythropoietin; Epoetin
Biological Activity:
Measured by the dose-dependant stimulation of human megakaryoblastic leukemia cells.
EClass:
32160000
Endotoxin:
<0.06EU/µg protein (LAL test; Lonza).
Form (Short):
solid
Formulation:
Lyophilized from 0.2µm-filtered solution in PBS.
Handling Advice:
Avoid freeze/thaw cycles.Centrifuge lyophilized vial before opening and reconstitution.
Long Description:
Protein. The extracellular domain of human EPO (aa 30-193) is fused to the N-terminus of the Fc region of a mutant human IgG1. Source: CHO cells. Endotoxin content: <0.06EU/µg protein (LAL test; Lonza). Lyophilized from 0.2µm-filtered solution in PBS. Purity: >98% (SDS-PAGE). Erythropoietin is the principal hormone involved in the regulation of erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells and the maintenance of a physiological level of circulating erythrocyte mass. It is a glycoprotein produced primarily by the kidney. The biological effects of EPO are mediated by the erythropoietin receptor (Epo R). Genetic variations in EPO is associated with susceptibility to microvascular complications of diabetes type 2 (MVCD2) (including diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease and diabetic neuropathy). It is used for the treatment of anemia and misused as a performance-enhancing drug in endurance athletes.
NCBI, Uniprot Number:
NP_000790.2
Package Type:
Plastic Vial
Product Description:
Erythropoietin is the principal hormone involved in the regulation of erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells and the maintenance of a physiological level of circulating erythrocyte mass. It is a glycoprotein produced primarily by the kidney. The biological effects of EPO are mediated by the erythropoietin receptor (Epo R). Genetic variations in EPO is associated with susceptibility to microvascular complications of diabetes type 2 (MVCD2) (including diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease and diabetic neuropathy). It is used for the treatment of anemia and misused as a performance-enhancing drug in endurance athletes.
Purity:
>98% (SDS-PAGE)
Sequence:
The extracellular domain of human EPO (aa 30-193) is fused to the N-terminus of the Fc region of a mutant human IgG1.
Source / Host:
CHO cells
TAGs:
Fc
Transportation:
Non-hazardous
UNSPSC Category:
Other Proteins
UNSPSC Number:
12352202
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.